AbbVie Japan Partnering Campaign 2026 Details

What the 1:1 meetings offer

• Direct discussion with AbbVie Japan Corporate Strategy Team (Business Development and Commercial Assessment teams)
• High-level feedback on strategic fit for Japan
• Exploration of potential Japan-specific deal structures
• A confidential follow-up process for selected opportunities
   

Who should apply (must fulfill all criteria)

• Biopharma companies with marketed assets or Phase 3/Pivotal-ready assets (include Phase 2 assets for oncology) in the US, EU, or China
• Assets with or without current clinical development in Japan
• Companies open to discussing Japan-only and Japan-inclusive regional rights
• Assets aligned with AbbVie Japan priorities and therapeutic areas of interest
   

AbbVie Japan partnering priorities and areas of interest

• Assets in the following therapeutic areas that compliment AbbVie Japan’s portfolio and pipeline without cannibalizing ongoing development
  • Immunology
  • Oncology
  • Neuroscience
  • Eye Care
  • Hepatology  (including MASH/NASH)
    
    

Key Evaluation Criteria

• Development stage (Late stage or  marketed outside Japan)
• Strategic fit with AbbVie’s therapeutic focus
• Clear differentiation versus existing standards of care
• Potential value and feasibility for the Japan market
   

Important – non-confidential submissions only

• All information submitted via email must be non-confidential
• Do not include data that could compromise patentability or confidentiality
• Detailed discussions will proceed under appropriate confidentiality agreements after selection
   

Call to action

• Click here to apply for a 1:1 meeting by Nov 30, 2026
• Selected applicants will be invited to 1:1 meetings scheduled through Dec 18, 2026
• We look forward to exploring innovative late-stage assets for Japan
   

Legal notice and submission terms

Before submitting any information to AbbVie, please review the following terms carefully. If appropriate, you may wish to seek advice from qualified legal counsel regarding the protection of your intellectual property rights, including any rights available under applicable patent or copyright laws.

By submitting information by email, you acknowledge that you have read, understood, and agreed to the terms set out below.
 

Policy for electronic submissions

AbbVie accepts license candidates or research programs under the following terms and conditions.

1. You represent that the information you provide via email is original to you and that you are under no contractual or legal obligation to maintain such information in confidence.
2. You acknowledge that you are 18 years of age or older, and can form a legally binding contract under applicable law.
3. You acknowledge that AbbVie is not receiving your information or suggestion in confidence, and that receipt of your information or suggestion does not create a confidential relationship between AbbVie and you.
4. All your rights and remedies arising out of your disclosure to AbbVie are limited exclusively to rights and remedies under applicable patent law and copyright law in Japan or the United States.
    

Personal Information

Any personal information provided to AbbVie in connection with this partnering campaign (such as your name and contact details) will be used solely for the purpose of evaluating the submitted information and communicating regarding potential partnering opportunities.

Such information may be shared within the AbbVie group and with service providers, strictly as necessary for these purposes, and will be handled in accordance with AbbVie’s Privacy Policy.

For further information, please refer to AbbVie’s Privacy Policy:  
https://privacy.abbvie/privacy-policies.html